You are here: Industry Insights > Market News > Parexel launches Health Advances Asia, expanding global footprint with Hong Kong, S.A.R., China base

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

New Products

3-Bromo-4-fluorobenzaldehyde

5-Methyl-1,3,4-oxadiazol2(3H)-one

4-Amino-6-methyl-3 oxo2,3, 4,5-tetrahydro 1.2.4-triazine hydrochloride

4-Acetylamino-6-methyl -3-oxo-2,3,4,5-tetrahydro-1,2,4-triazine

3-Pyridinecarboxaldehyde

Ethyl 3 Fluorobenzoate

Parexel launches Health Advances Asia, expanding global footprint with Hong Kong, S.A.R., China base

fiercepharmaJuly 28, 2019

Tag: PAREXEL , Health Advances Asia , global footprint

Favorites

The so-called Health Advances Asia Limited subsidiary, which forms part of Parexel's consulting unit, is set up to "support development of global expansion strategies for Asia/Pacific and multinational companies from new Hong Kong, S.A.R., China presence," according to the firm.

It will be led by biopharma and medtech veteran Gary Cheng, who will be in charge of the local team. Cheng, who counts Novartis, BD, Chiron, Alere and Aventis among his former employers, will also work with Vivek Mittal, a long-time partner at Health Advances in its San Francisco office who will now be based in Hong Kong, S.A.R., China Special Administrative Region in China.

Previous:Key European committee backs GW's Epidyolex, Bayer's Vitrakvi and more

Next:GOP senators distance themselves from Grassley, Trump's efforts to cut drug prices

Sartorius Stedim Biotech Opens New Center for Bioprocess Innovation in Marlborough, USA

PharmaSourcesNovember 22, 2024

Sartorius Stedim Biotech, a leading partner of the biopharmaceutical industry, today opened its new Center for Bioprocess Innovation in Marlborough, Massachusetts.

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Biotech NewswireNovember 20, 2024

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

PR NEWSWIRENovember 20, 2024

Parexel launches Health Advances Asia, expanding global footprint with Hong Kong, S.A.R., China base | Pharmasources.com

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

Nurah EkhlaqueNovember 19, 2024

Discover how AI in pharmacovigilance improves drug safety by predicting risks, identifying harmful interactions, and enhancing patient outcomes.

Parexel launches Health Advances Asia, expanding global footprint with Hong Kong, S.A.R., China base

Related News

Sartorius Stedim Biotech Opens New Center for Bioprocess Innovation in Marlborough, USA

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

You may like
More>>

Parexel launches Health Advances Asia, expanding global footprint with Hong Kong, S.A.R., China base

Related News

Sartorius Stedim Biotech Opens New Center for Bioprocess Innovation in Marlborough, USA

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

You may likeMore>>

You may like
More>>